Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058359 | PMC |
| http://dx.doi.org/10.1200/JCO-25-00722 | DOI Listing |
Publication Analysis
Top Keywords
erratum pertuzumab
4
pertuzumab retreatment
4
retreatment human
4
human epidermal
4
epidermal growth
4
growth factor
4
factor receptor
4
receptor 2-positive
4
2-positive locally
4
locally advanced/metastatic
4
Similar Publications
Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial.
BMC Cancer
December 2022
Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel": [Annals of Oncology 28 (2017) 2768-2772].
Ann Oncol
March 2022
West German Study Group GmbH, Moenchengladabach, Germany; Breast Center, Department of Gynecology and Obstetrics, University of Munich (LMU) and CCCLMU, Munich, Germany.
Correction to: Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
Cancer Chemother Pharmacol
April 2022
Genentech, Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Corrigendum to: A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).
Jpn J Clin Oncol
August 2021
Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.